COST-EFFECTIVENESS OF SWITCHING TO INSULIN ASPART FROM HUMAN SOLUBLE INSULIN IN CHINESE PATIENTS WITH TYPE-2 DIABETES ON A BASAL-BOLUS REGIMEN

被引：0

作者：

Ji, Q. H. ^{[1
]}

Ye, Q. ^{[2
]}

Zhang, Y. Z. ^{[3
]}

机构：

[1] Fourth Mil Med Univ, Xijing Hosp, Xian 710032, Peoples R China

[2] Erasmus Univ, Inst Hlth Policy & Management, Rotterdam, Netherlands

[3] Novonordisk China Pharmaceut Co Ltd, Beijing, Peoples R China

来源：

VALUE IN HEALTH | 2013年 / 16卷 / 03期

关键词：

D O I：

10.1016/j.jval.2013.03.822

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A164 / A165

页数：2

共 50 条

[1] COST-EFFECTIVENESS OF THERAPY CONVERSION FROM HUMAN SOLUBLE INSULIN TO INSULIN ASPART IN PATIENTS WITH TYPE-2 DIABETES IN A CHINESE SETTING
Xu, Z. R.
Ye, Q.
Zhang, Y. Z.
[J]. VALUE IN HEALTH, 2013, 16 (03) : A163 - A164
[2] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/INSULIN ASPART TWICE DAILY VERSUS BASAL-BOLUS FULL REGIMEN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN ALGERIA
Sellam, Y.
Malek, R.
Semrouni, M.
Belhadj, M.
Zekri, S.
Brouri, M.
Arbouche, Z.
Nouri, N.
[J]. VALUE IN HEALTH, 2020, 23 : S511 - S511
[3] Insulin detemir and insulin aspart:: a promising basal-bolus regimen for type 2 diabetes
Raslová, K
Bogoev, M
Raz, I
Leth, G
Gall, MA
Hancu, N
[J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2004, 66 (02) : 193 - 201
[4] Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK
Evans, M.
Wolden, M.
Gundgaard, J.
Chubb, B.
Christensen, T.
[J]. JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (01) : 56 - 68
[5] COST-EFFECTIVENESS OF INSULIN DEGLUDEC COMPARED WITH INSULIN GLARGINE IN A BASAL-BOLUS REGIMEN IN PATIENTS WITH TYPE 1 DIABETES MELLITUS IN THE UNITED KINGDOM
Chubb, B.
Evans, M.
Wolden, M.
Christensen, T.
Gundgaard, J.
[J]. VALUE IN HEALTH, 2013, 16 (07) : A442 - A442
[6] A comparison of the cost-effectiveness for basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart or human insulin-based regimens
Palmer, AJ
Roze, S
Valentine, WJ
Schmidt, I
Wittrup-Jensen, KW
[J]. DIABETES, 2004, 53 : A288 - A288
[7] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
Valentine, WJ
Wittrup-Jensen, KU
Häuser, C
Roze, S
[J]. DIABETOLOGIA, 2005, 48 : A334 - A334
[8] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
Valentine, WJ
Wittrup-Jensen, KU
Palmer, AJ
Roze, S
[J]. DIABETES, 2005, 54 : A609 - A609
[9] A comparison of the cost-effectiveness of basal-bolus therapy of Type 1 diabetes using insulin detemir plus insulin aspart versus human insulin-based regimens
Palmer, AJ
Roze, S
Valentine, WJ
Smith, IC
Wittrup-Jensen, K
[J]. DIABETOLOGIA, 2004, 47 : A344 - A344
[10] Switching from a human insulin basal-bolus regimen to insulin analog basal-bolus therapy with insulin detemir/insulin aspart improves glycemic control and reduces hypoglycemic episodes in patients with type 1 diabetes:: Results from German subgroup of the PREDICTIVE™ study
Maxeiner, Stephan
Hansen, Jes B.
Nauck, Michael
[J]. DIABETES, 2006, 55 : A127 - A127

← 1 2 3 4 5 →